help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Secchiero, P.
Right arrow Articles by Zauli, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Secchiero, P.
Right arrow Articles by Zauli, G.
(American Journal of Pathology. 2005;167:1599-1607.)
© 2005 American Society for Investigative Pathology

Potential Pathogenetic Implications of Cyclooxygenase-2 Overexpression in B Chronic Lymphoid Leukemia Cells

Paola Secchiero*, Elisa Barbarotto*, Arianna Gonelli*, Mario Tiribelli{dagger}, Carlotta Zerbinati{ddagger}, Claudio Celeghini{ddagger}, Claudio Agostinelli§, Stefano A. Pileri§ and Giorgio Zauli{ddagger}

From the Department of Morphology and Embryology,* Human Anatomy Section, University of Ferrara, Ferrara; the Department of Medical and Morphological Researches,{dagger} Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine; the Department of Normal Human Morphology,{ddagger} University of Trieste, Trieste; and the Unit of Haematopathology,§ Institute of Haematology and Clinical Oncology "L. and A. Seragnoli", University of Bologna, Bologna, Italy

Evidence suggests that cyclooxygenase-2 (COX-2) increases tumorigenic potential by promoting resistance to apoptosis. Because B chronic lymphoid leukemia (B-CLL) cells exhibit a defective apoptotic response, we analyzed CD19+ B lymphocytes purified from the peripheral blood of B-CLL patients. Microarray analysis showed a variable (up to 38-fold) increase in the steady-state mRNA levels of COX-2 in B-CLL lymphocytes compared with normal CD19+ B lymphocytes. The up-regulation of COX-2 in B-CLL cells was confirmed by reverse transcriptase-polymerase chain reaction and Western blot analyses. Moreover, immunohistochemical analysis of B-CLL bone marrow infiltrates confirmed clear expression of COX-2 in leukemic cells. Ex vivo treatment with the COX-2 inhibitor NS-398 significantly decreased the survival of leukemic cells by increasing the rate of spontaneous apoptosis in 13 of 16 B-CLL samples examined, but it did not affect the survival of normal lymphocytes. Pretreatment with NS-398 significantly potentiated the cytotoxicity induced by chlorambucil in 8 of 16 B-CLL samples examined. Moreover, although recombinant tumor necrosis factor-related apoptosis inducing ligand (TRAIL)/Apo2L showed little cytotoxic effect in most B-CLL samples examined, pretreatment with NS-398 sensitized 8 of 16 B-CLL samples to TRAIL-induced apoptosis. Taken together, our data indicate that COX-2 overexpression likely represents an additional mechanism of resistance to apoptosis in B-CLL and that pharmacological suppression of COX-2 might enhance chemotherapy-mediated apoptosis.




This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
C. F.A. Vogel, W. Li, E. Sciullo, J. Newman, B. Hammock, J. R. Reader, J. Tuscano, and F. Matsumura
Pathogenesis of Aryl Hydrocarbon Receptor-Mediated Development of Lymphoma Is Associated with Increased Cyclooxygenase-2 Expression
Am. J. Pathol., November 1, 2007; 171(5): 1538 - 1548.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society for Investigative Pathology.